Hypertension control in integrated HIV and chronic disease clinics in Uganda in the SEARCH study

BMC Public Health

Table 5 Predictors of hypertension control at two consecutive visits among patients who linked to hypertension care following population-level screening and had at least two subsequent follow-up visits (n = 1327)

	Unadjusted OR (95% CI) for HTN control	p-value	Adjusted OR (95% CI) for HTN control	p value
Sex		0.08		0.09
Female	1.0		1.0
Male	0.82 (0.65, 1.02)		0.83 (0.68, 1.03)
Age		0.008		0.009
< 50 years	1.0		1.0
> =50 years	0.72 (0.56, 0.92)		0.73 (0.58, 0.91)
Diabetes present		0.99		0.99
No	1.0		1.0
Yes	0.99 (0.71, 1.39)		1.01 (0.72, 1.39)
Time since first clinic visit (months)	1.03 (1.03, 1.04)	< 0.001	1.03 (1.02, 1.04)	< 0.001
Hypertension Stage at previous visit		< 0.001		< 0.001
0	1.0		1.0
1	0.87 (0.69, 1.08)		0.89 (0.78, 0.99)
2	0.42 (0.07, 2.52		0.79 (0.67, 0.91)
Anti-hypertensive Medication prescribed at previous visit		0.009		0.28
Yes	0.74 (0.59, 0.93)	0.03	1.03 (0.89, 1.14)	0.21
No	1.0		1.0
HIV Status		0.06		0.07
Known-infected	1.81 (0.97, 3.41)		1.54 (0.93, 2.65)
Known-uninfected	1.0		1.0
Scheduled visit interval
Per HTN treatment guidelines	1.0	< 0.001	1.0	0.02
More frequently than guidelines	0.68 (0.37, 0.98)		0.80 (0.52, 0.99)
Clinic
Bugamba	0.36 (0.24, 0.53)		0.46 (0.31, 0.68)
Kameke	6.98 (4.62, 10.54)		5.05 (3.30, 7.72)
Kamuge	1.34 (0.97, 1.85)		1.21 (0.88, 1.68)
Kazo	0.74 (0.45, 1.22)		0.77 (0.46, 1.31)
Merikit	1.77 (1.19, 2.61)		1.10 (0.74, 1.61)
Mitooma	1.0		1.0
Muyembe	2.32 (1.60, 3.37)		1.24 (0.85, 1.81)
Nankoma	2.76 (1.80, 4.22)		2.30 (1.48, 3.56)
Rubaare	0.87 (0.56, 1.35)		0.80 (0.50, 1.28)
Ruhoko	1.15 (0.74, 1.78)		0.45 (0.29, 0.69)

ISSN: 1471-2458